AstraZeneca (LON: AZN) to acquire Caelum Biosciences: Buy alert?

September 29, 2021 04:24 PM BST | By Suhita Poddar
 AstraZeneca (LON: AZN) to acquire Caelum Biosciences: Buy alert?
Image source: Rattiya Thongdumhyu, Shutterstock

Highlights

  • Anglo-Swedish pharma company, AstraZeneca’s Alexion is set to acquire the remaining stake in rare disease biotech firm Caelum Biosciences.
  • The deal is worth up to US$ 150 million, with a potential facility for making additional payments of US$ 350 million subject to meeting certain conditions.
  • AstraZeneca emerged as the highest riser in the FTSE 100 index, with shares surging over 3 per cent following the news. 

British Swedish pharmaceutical major AstraZeneca PLC (LON: AZN) said its subsidiary Alexion would fully acquire US-based rare diseases biotech firm Caelum Biosciences after Alexion exercised the option for the remaining equity in Caelum. 

The deal will help in the acquisition of the CAEL-101, which is a fibril-reactive monoclonal antibody (mAb) used for the treatment of a rare disease, light chain (AL) amyloidosis.

Alexion is a group within the company which is also focused on rare diseases.

AstraZeneca’s (LON: AZN) share price performance

AstraZeneca’s shares were trading at GBX 8,752.00, up by 3.28 per cent on 29 September 2021 at 14:11 PM BST. Comparatively, the FTSE 100 index was trading at 7,085.99, up by 0.82 per cent.

AstraZeneca emerged as the highest riser in the FTSE 100 index, which it is a part of, following the news.

AZN market cap and YTD return

© 2021 Kalkine Media

The company’s market cap stands at £131,273.11 million and has a year to date return of 19.54 per cent as of 29 September.

AstraZeneca’s acquisition deal details

Alexion had entered into a collaboration agreement with Caelum in 2019, taking a minority interest stake with the firm, it also included an exclusive option to acquire Caelum’s remaining equity.

The deal for the remaining stake Caelum Biosciences is expected to be worth up to US$ 150 million, with a potential facility for making additional payments of US$ 350 million upon hitting certain milestones. The acquisition is expected to close on 5 October. 

CAEL-101 details 

About 20,000 people in the US, France, Germany, the UK and other countries suffer from AL amyloidosis and have an AL amyloidosis disease classification of Mayo stage IIIa or IIIb.

According to earlier comments made by analysts, the incident cases of AL amyloidosis indicates a potential revenue range between US$ 750 million and US$ 1 billion for the CAEL-101 treatment.

CAEL-101 is currently undergoing an evaluation under the Cardiac Amyloid Reaching for Extended Survival (CARES) clinical programme, in conjunction with standard of care therapy, to ascertain the efficacy and safety of the treatment.  

It is currently involved in two parallel global phase 3 trials. 

Bottom Line

AstraZeneca had acquired Alexion in 2020 in a deal worth up to US$ 39 billion in order to strengthen its immunology business segment.

The company was among one of the first vaccine makers approved for mass use against the covid-19 vaccine. However, due to its commitment of making the vaccine available at cost, it has not seen a significant boost in profits from its covid-19 vaccine.

Analysts expect the Caelum deal will thus help boost AstraZeneca’s rare diseases portfolio and prove to be another avenue for generating revenues.stock


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next